Keytruda hits one primary endpoint for use before and after surgery in lung cancer
Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
